2018 EDITORIAL COVERAGE. Connecting the Pharma Industry for 28 Years.

Size: px
Start display at page:

Download "2018 EDITORIAL COVERAGE. Connecting the Pharma Industry for 28 Years."

Transcription

1 2018 EDITORIAL COVERAGE Connecting the Pharma Industry for 28 Years

2 EDITORIAL COVERAGE: EXPERT INSIGHT AND ANALYSIS Pharmaceutical Technology Europe sets the standard for publishing independent, industry-leading information on the technologies, strategies, and regulations crucial to professionals developing and manufacturing pharmaceuticals and biopharmaceuticals. The editorial mix of peer-reviewed papers, technical articles, technology reports, regulatory and business columns, and expert commentary provide comprehensive coverage of process and formulation development, manufacturing operations, drug delivery, packaging, labelling, and distribution. EDITORIAL FOCUs Each issue of Pharmaceutical Technology Europe addresses a key trend in drug development. Through expert interviews, roundtable discussions, literature reviews, and survey analysis, the editors report on emerging trends, strategies, and best practices in these key areas. PEER-REVIEWED REsEARCH Pharmaceutical Technology Europe publishes peer-reviewed papers in the form of data-driven research papers, literature and patent reviews, application and technical notes, and position papers on a broad range of drug development topics. All papers undergo a double-blind peer-review process by the Pharmaceutical Technology Europe Editorial Advisory Board, which consists of leading scientists, managers, directors, and consultants. KEY TOPICs Drug Features address formulation and drug delivery challenges including solubility, particle engineering, traditional and emerging dosage forms, and more. Advances in API synthesis of small- and large-molecule drug substances, as well as excipients to enhance drug properties, are also addressed. A special column provides thought-leader insight on drug development activities in Europe. MANUFACTURING AND OPERATIONs The editors examine problems and solutions for solid dosage, sterile, biopharmaceutical, and other drug forms. Experts share insights on manufacturing equipment, process controls, scale-up, packaging, tech transfer, and facility and laboratory operations. ANALYTICAL TEsTING Feature articles and case studies address vital quality and characterization practices including elemental impurities, stability testing, protein characterization, microbial contamination, method development, and more. QUALITY/REGULATIONs Experts review current regulatory authority initiatives and offer insight on quality agreements, critical quality attributes, investigations, process validation, statistical practices, and more. supply CHAIN Supply chain coverage includes equipment, software, and services to maintain a secure, compliant serialization program, take proactive measures against counterfeiting, ensure safe shipping, and other supply chain issues. OUTsOURCING Trends, partnerships, and business activities in the contract services market are described by expert columnists. Other features examine best practices for working with contract service providers for drug development, manufacturing, or laboratory studies. CONTRIbUTION GUIDELINEs For information about contributing editorial features to Pharmaceutical Technology Europe, visit

3 JANUARY FEbRUARY MARCH Ad Close: 8 January Ad Close: 30 January Ad Close: 23 February 2018 Bio/Pharma Outlook API and Approval Trends Drug Addiction Prevention Biologic-Based Drug Industry 4.0/Internet of Things Process Validation Elemental Impurities Track and Trace/Serialization Review Pharmapack, 7 8 Feb., Paris Readex Ad Performance Study Free 1/2-Page Pharmapack Exhibitor Profile Seeking Analytical Answers Ensuring Excipient Quality Biologic Drug Formulation Solid/Semi-Solid Drug Single-Use Regulatory : Sterile/Aseptic Lab Data Integrity Facility Design and Anticounterfeiting PDA Europe - Parenteral Packaging, February, Rome, Italy Global Drug Delivery & Formulation Summit, March, Berlin BIO-Europe Spring, March, Amsterdam Pittcon, 26 Feb. 1 March, Orlando, FL, USA Early Strategies Advances in API Synthesis Particle Engineering Topical Drug Process Quality Agreements Stability Testing Lab Cold Chain Review Special Themed Supplement Resources An annual review of the market for outsourced resources, including analysis of contract services and business, regulatory, and supply chain issues. DCAT Week, March, New York INTERPHEX, April, New York 1/3-Page Product/Service Profile

4 APRIL MAY JUNE Ad Close: 26 March Ad Close: 25 April Ad Close: 24 May Modernizing Pharma Selecting API Suppliers Protein/Peptide Delivery Inhalation Drug Equipment and Batch Records Protein Characterization Statistical Solutions Tech Transfer Certificates of Analysis CPhI North America, April, Philadelphia Informex, April, Philadelphia Making Pharmaceuticals, April, Coventry, UK Process Optimization Biopharmaceutical APIs Capsule Formulations Aseptic/Sterile Drug Data Integrity Regulatory : Solid/Semi-solid Dosage Cleaning Validation Logistics/Shipping Review BIO International Convention, June 4 7, Boston ACHEMA, June, Frankfurt 1/3-Page Product/Service Profile 1/2-Page Achema Exhibitor Profile Emerging Drug Delivery Trends Continuous API Solubility/Bioavailability Biologic-Based Drug Fill/Finish Critical Quality Attributes Dissolution Testing Process Clinical Trial Materials Logistics Outsoucing 3rd PDA Europe Annual Meeting, June, Berlin, Germany ChemSpec Europe, June, Cologne, Germany

5 JULY august september Ad Close: 26 June Ad Close: 27 July Ad Close: 23 August Sustaining Good Practices Excipients for Controlled- Release Formulations Expression Systems Aseptic/Sterile Drug Process Control/Automation Corrective Action and Preventive Action Particle Characterization Track and Trace/Serialization Review Controlled Release Society, July, New York 1/3-Page Product/Service Profile Building Better Biologic Drugs Hazardous Reagents Tablet Formulation Solid/Semi-Solid Drug Modular Systems Investigations/Root Causes Extractables and Leachables Testing Lab Good Distribution Practices Special Themed Supplement APIs, Excipients, and featuring the CPhI/ICSE Worldwide Planning Guide s in the synthesis of APIs and pharmaceutical intermediates, plus advances in small-molecule synthesis, biologics manufacturing, formulation development, and finished-product manufacturing. This issue will feature a CPhI Planning Guide. Digital distribution to 44,500 CPhI visitors and 2,500 CPhI exhibitors Security Repurposing APIs Taste-masking Biologic-Based Drug Clinical Trial Materials Quality by Design Microbial Contamination Statistical Solutions Facility Design and Anticounterfeiting/Theft Avoidance Review PPMA, Sept., Birmingham, UK CPhI Worldwide, 9 11 Oct., Madrid, Spain Free 1/2-page CPhI Worldwide Exhibitor Profile PDA Europe - Pharmaceutical Freeze Drying Technology, September, Cologne, Germany Readex Ad Performance Study SHOW ISSUE

6 OCTObER NOVEMbER DECEMbER Ad Close: 27 September Ad Close: 25 October Ad Close: 22 November Drug Dosage Forms Trends Advances in the API Synthesis Lab Lipid-Based Formulations Solid/Semi-Solid Drug Lyophillization Mock Inspections Lot Release Testing Raw Materials Tracking Outsoucing AAPS 2018 PharmSci360, 4 7 Nov., Washington DC PDA Europe & Contract / Pharmaceutical Cold Chain & Logistics 1/3-Page Product/Service Profile Avoiding CMC Roadblocks High-Potency API Prefilled Syringes Aseptic/Sterile Drug Process Modeling Risk Assessment and Mitigation Visual Inspection Techniques Tech Transfer Drug Product Tracking Review CPhI India, 4-6 Dec., Mumbai The Quality Issue Special Report: Salary and Employment Survey Biopharmaceutical APIs Combination Products Transdermal Drug Scale-Up Standard Operating Procedures Endotoxin Testing Process Validating Supplier Quality Free Full-Page Corporate Profile Editorial content may change at the discretion of the editor. *Advertising deadlines may be subject to change. ** Receipt of an article or abstract does not guarantee inclusion in a particular issue of the magazine or on

Introduction to CMC Regulatory Affairs

Introduction to CMC Regulatory Affairs Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4

More information

Media Planner

Media Planner Media Planner 2018 www.themedicinemaker.com medicines Why choose APRIL 2017 # 29 Substance Upfront How to catch cargo criminals In My View Why are we still waiting for biosimilars? Sitting Down With Ace

More information

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization

More information

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August

More information

Capabilities Overview Presentation. Presenter

Capabilities Overview Presentation. Presenter Capabilities Overview Presentation Presenter About Baxter Global, diversified healthcare company 80 years of parenteral expertise driven by a well recognized global brand $12.6 billion global market leader

More information

ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers

ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers

More information

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators

More information

PHARMACEUTICAL TESTING

PHARMACEUTICAL TESTING WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey

More information

API Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016

API Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 API Testing Requirements to Support the EI Risk Assessment Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 Agenda Background Review of ICH Q3D Risk Assessment Principles

More information

Industry Perspective on Manufacturing in Early Development

Industry Perspective on Manufacturing in Early Development Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical

More information

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels

More information

CERTIFICATE IN BIOPHARMACEUTICALS

CERTIFICATE IN BIOPHARMACEUTICALS Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers

More information

Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148

Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP

More information

Analytical and formulation attributes

Analytical and formulation attributes Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding

More information

Presse-Information Press release Information de presse

Presse-Information Press release Information de presse Presse-Information Press release Information de presse Kontakt/Contact: Dr. Kathrin Rübberdt Tel. ++49 (0) 69 / 75 64-2 77 Fax ++49 (0) 69 / 75 64-2 72 e-mail: presse@dechema.de Trend Report February 2018

More information

Leading The Way in Life Science Technologies. Planning Calendar

Leading The Way in Life Science Technologies. Planning Calendar Leading The Way in Life Science Technologies 2018 Planning Calendar January 1 Reservation: 11/30/17 Material: 12/7/17 l Kinase Assays l Immunotherapy l Stem-Cell Manufacturing Peptalk, January 8 12, San

More information

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author

More information

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

USP Chapter 823 USP 32 (old) vs. USP 35 (new) USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has

More information

Management Team. Over 35 years experience in the pharmaceuticals industry

Management Team. Over 35 years experience in the pharmaceuticals industry 2017 1 Overview Located in Bangalore, a Dedicated cgmp and cglp Compliance Laboratory Established in September 2010 Approved Contract research Organization by India FDA Approved by Health Canada since

More information

Setting Specifications for Biotech Products

Setting Specifications for Biotech Products Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of

More information

Early Development Best Practices for Stability- Regulatory Perspective

Early Development Best Practices for Stability- Regulatory Perspective Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment

More information

How to Identify Critical Quality Attributes and Critical Process Parameters

How to Identify Critical Quality Attributes and Critical Process Parameters How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,

More information

Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016

Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory

More information

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &

More information

Microbiological Consideration for Non-Sterile Pharmaceutical

Microbiological Consideration for Non-Sterile Pharmaceutical May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control

More information

Case Study: Examples Relating to the Quality Control of Cell-based Products

Case Study: Examples Relating to the Quality Control of Cell-based Products Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association

More information

Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.

Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel

More information

Serving the dynamic informational and networking needs of the global healthcare and life sciences ecosystem for over a decade

Serving the dynamic informational and networking needs of the global healthcare and life sciences ecosystem for over a decade Calendar 2018 Serving the dynamic informational and networking needs of the global healthcare and life sciences ecosystem for over a decade For more information on sponsoring, exhibiting, speaking or attending

More information

Extractables and leachables: An Introduction

Extractables and leachables: An Introduction Extractables and leachables: An Introduction Tim Hulme Smithers Rapra THulme@smithers.com 44(0)1939 252 418 1 Extractables and leachables: An Introduction Tim Hulme Smithers Rapra thulme@smithers.com 2

More information

Biowaiver Approaches for Generic Drug Products in the US: Case Studies

Biowaiver Approaches for Generic Drug Products in the US: Case Studies About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX BATCH Q: Quality Q1A(R2) Stability Testing of New Drug Substances

More information

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables

More information

LEGAL REQUIREMENTS FOR STABILITY

LEGAL REQUIREMENTS FOR STABILITY BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.

More information

This article specifically covers incorporation of physical and chemical indicators (PCIDs) into or onto the drug product.

This article specifically covers incorporation of physical and chemical indicators (PCIDs) into or onto the drug product. Introduction The pharmaceutical industry is criminalized with circulation of counterfeit drugs risking healthcare and the life of users. This has become quite menacing in recent times with the lure of

More information

FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS

FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability

More information

News Release. Even more attractive to life science and fine chemical industries. Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21

News Release. Even more attractive to life science and fine chemical industries. Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21 Saltigo at CPhI 2017, Frankfurt, October 24-26, 2017, Stand 111H21 Even more attractive to life science and fine chemical industries Saltigo GmbH Contact: Ilona Kawan LANXESS AG Corporate Communications

More information

Actavis Italy. Nerviano Plant

Actavis Italy. Nerviano Plant Actavis Italy Nerviano Plant Starting out in 1901 in Jerusalem The company known today as Teva was established as a small wholesale drug business by Chaim Salomon, Moshe Levin and Yitschak Elstein. (They

More information

School of Pharmacy TEMPLE UNIVERSITY

School of Pharmacy TEMPLE UNIVERSITY School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme

More information

Post-Approval Change Regulations in Japan

Post-Approval Change Regulations in Japan Post-Approval Change Regulations in Japan Pharmaceuticals and Medical Devices Agency Office of Cellular and Tissue-based Products Futaba Honda, Ph.D. Agenda Application Forms and attached documents for

More information

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline

More information

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Nageshwar R Thudi Ph.D. Director-Clinical R&D Teva Pharmaceuticals Disclaimer The views expressed herein are the views

More information

Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority

Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority CHALLENGES AND OPPORTUNITIES IN COLD CHAIN: HEALTH CARE RELATED DRIVERS Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority AGENDA Integrating stakeholders

More information

GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER

GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER RESTRICTED GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER Since being presented to the Fortieth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2005 this

More information

Investigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd

Investigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd Investigating OOS for Finished Product on the Stability Program Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd Overview 1. Requirements of the commercial stability program 2. Out of Specification

More information

KINGSMANN CARE GROUP

KINGSMANN CARE GROUP PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting

More information

Annex 14 WHO guidelines for drafting a site master file 136

Annex 14 WHO guidelines for drafting a site master file 136 World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix

More information

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Manufacturing Breakout Session 1 Survey Results: Drug Product Manufacturing

More information

Request for Quote RFQ #

Request for Quote RFQ # Request for Quote RFQ # 2017-007 Drug Product Manufacture: GMP Fill/Finish of Monoclonal Antibody I. Summary of Deadlines Release of Request for quote Feb 13, 2017 Confirmation of interest due by Feb 20,

More information

Partner with the Global Leader in Drug Delivery Systems

Partner with the Global Leader in Drug Delivery Systems 3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems Northridge, CA, USA Manufacturing Facility Experts at Commercializing Innovation 3M: Transforming New Ideas into Thousands

More information

global clinical trials. integrated solutions. reduced timelines.

global clinical trials. integrated solutions. reduced timelines. global clinical trials. integrated solutions. reduced timelines. clinical supply DEVELOPMENT DELIVERY SUPPLY As a worldwide clinical supply services leader, Catalent has the scale, expertise, innovative

More information

Mitigating Commercial Risks in Continuous Manufacturing Drug Product

Mitigating Commercial Risks in Continuous Manufacturing Drug Product Mitigating Commercial Risks in Continuous Manufacturing Drug Product Ian Leavesley Eli Lilly Indianapolis, Indiana Commercializing Continuous Processing in Pharma Boston, MA Jan 30 th Feb 1 st 2017 Outline

More information

ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management

ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Global Regulator Affairs Rx Perrigo Company, plc Q U A L I T Y A F F

More information

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14

More information

COMMERCIAL PRODUCT STABILITY

COMMERCIAL PRODUCT STABILITY COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls

More information

Pharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful

Pharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Pharma&Biotech ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and

More information

CaSSS CMC Strategy Forum A Practical Approach to the Analysis and Immunogenic Potential of Aggregates and Particles

CaSSS CMC Strategy Forum A Practical Approach to the Analysis and Immunogenic Potential of Aggregates and Particles CaSSS CMC Strategy Forum A Practical Approach to the Analysis and Immunogenic Potential of Aggregates and Particles January 9, 2011 Renaissance Mayflower Hotel Washington, D.C. Visual Inspection of Parenterals

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU

More information

Essential Update on Contract Manufacturing and Quality Standards CPhI, Paris.

Essential Update on Contract Manufacturing and Quality Standards CPhI, Paris. Essential Update on Contract Manufacturing and Quality Standards CPhI, Paris. Guy Villax 7 th of October 2014 Agenda Short Introduction to Hovione Driving Forces Shaping the Market CMOs Innovators and

More information

1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country

1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country 1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country S no 1. Name of Applicant with address 2. Name of Drug 3. Therapeutic Class 4. Date of Approval Documents

More information

Approaches to regulatory engagement and filing for continuous manufacturing

Approaches to regulatory engagement and filing for continuous manufacturing Approaches to regulatory engagement and filing for continuous manufacturing Mark Buswell CEng FIChemE FDA-AIChE Workshop on Adopting Continuous Manufacturing, Disclosures The speaker is solely responsible

More information

Science. Enhancing the Pharma-CRO relationship with a focus on method transfer. for a safer world

Science. Enhancing the Pharma-CRO relationship with a focus on method transfer. for a safer world Enhancing the Pharma-CRO relationship with a focus on method transfer Chris Jones, Client Manager, Drug Development Services, LGC EBF Open Symposium, 18 th November 2015 Science for a safer world Overview

More information

CMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013

CMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013 CMC Strategy Forum Prague 2013 Enda Moran EBE Satellite Session, 06 May 2013 European Biopharmaceutical Enterprises EBE s VISION: fostering innovation, and promote favorable business and regulatory conditions

More information

Developing and Validating Dissolution Procedures for Improved Product Quality

Developing and Validating Dissolution Procedures for Improved Product Quality W H I T E P A P E R Developing and Validating Dissolution Procedures for Improved Product Quality By Michael Swartz, Ph. D., Director of Research and Development, and Mark Emanuele, Chemist Abstract In

More information

SECRETARY, DEPARTMENT OF PHARMA,GOVT. OF INDIA INDO AFRICA BUSINESS SUMMIT AT HYDERABAD

SECRETARY, DEPARTMENT OF PHARMA,GOVT. OF INDIA INDO AFRICA BUSINESS SUMMIT AT HYDERABAD *ADDRESS BY SHRI ASHOK KUMAR, IAS, SECRETARY, DEPARTMENT OF PHARMA,GOVT. OF INDIA INDO AFRICA BUSINESS SUMMIT AT HYDERABAD Shri Anand Sharmaji, Hon ble Minister of Commerce & Industry, Govt. of India,

More information

BEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development

BEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development - ASPECTS OF COMPOUNDING PRODUCT DESIGN Reinout C.A. Schellekens, PharmD, RHPh, QP Head Clinical Drug Production and Development Department of Hospital and Clinical Pharmacy University Medical Center Groningen,

More information

Quality Agreements and Managing Contract Supplier Quality

Quality Agreements and Managing Contract Supplier Quality Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract

More information

Pre-Approval Inspections for Drug Products

Pre-Approval Inspections for Drug Products Pre-Approval Inspections for Drug Products FDA Small Business Regulatory Education for Industry Conference June 20, 2013 H.L. Jamillah Selby Consumer Safety Officer FDA, Dallas District Office Presentation

More information

Elemental Impurities: An Industry Perspective

Elemental Impurities: An Industry Perspective Elemental Impurities: An Industry Perspective Ernest Parente, PhD Mallinckrodt Pharmaceuticals May 17, 2016 2016 GPhA CMC Workshop Overview Risk Assessment The Supplier Interface The Contractor Interface

More information

Formulation Development

Formulation Development Quality by Design and Formulation Development WF Busch Senior Application Development Specialist Dow Chemical Company IPEC Americas, Quality by Design Committee 5 May 2010 Disclaimer The views and opinions

More information

Writing an Assessment Report

Writing an Assessment Report Safeguarding public health Writing an Assessment Report Name: Malcolm Dash Date: Programme Why we need Assessment Reports Writing style Deficiency points Potential Serious Risk to Public Health Targeted

More information

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low

More information

Validation of Sterilizing Grade Filters

Validation of Sterilizing Grade Filters Validation of Sterilizing Grade Filters Presented by Laura Okhio-Seaman Sartorius Corporation 1 Sterilizing Grade Filters The definition of a sterilizing grade filter is one that will produce a sterile

More information

TABLE OF CONTENTS. 1.3 Industry Pricing Trends Recent Industry Pricing Changes Contractor Utilization Rates 1-5

TABLE OF CONTENTS. 1.3 Industry Pricing Trends Recent Industry Pricing Changes Contractor Utilization Rates 1-5 TABLE OF CONTENTS Chapter 1: EXECUTIVE SUMMARY 1.1 Introduction 1-1 1.2 Participants Locations 1-3 1.3 Industry Pricing Trends 1-4 1.3.1 Recent Industry Pricing Changes 1-4 1.3.2 Contractor Utilization

More information

Precision. Proficiency. Proximity.

Precision. Proficiency. Proximity. Precision. Proficiency. Proximity. Precision Accuracy in testing is paramount to ensuring product safety and efficacy. And fast turnaround times are critical to keeping your project on schedule. With

More information

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION Reprinted from FDA s website by EAS Consulting Group, LLC ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION ANDA: APPLICANT: RELATED APPLICATION(S): DRUG NAME:

More information

Oral Dosage Formulation Development

Oral Dosage Formulation Development Oral Dosage Formulation Development Achieving faster formulation of solid oral dosage forms for FIH supplies Dr. Colin Lorimer - published April 29, 2011 The pharmaceutical industry is increasingly looking

More information

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions

More information

About Siegfried. Company Portrait

About Siegfried. Company Portrait About Siegfried Company Portrait Headquartered in Zofingen, Switzerland, Siegfried operates worldwide in life sciences with production facilities in Switzerland, the USA, Malta, China, Germany and France.

More information

Presentation of Capabilities Reverse Logistics

Presentation of Capabilities Reverse Logistics Presentation of Capabilities Reverse Logistics Woodfield Distribution, LLC v081617 Reverse Logistics About Us Description of Services Reverse Distribution Channels DSCSA/Sustainability About Us WDSrx Woodfield

More information

Microbial Detection Methods and Their Limitations

Microbial Detection Methods and Their Limitations Microrite, Inc. brings you this unique learning experience in Microbial Detection Methods and Their Limitations; Part of Microrite s step-by-step webinar series. Microbial Detection Methods and Their Limitations

More information

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA, and does no confer any

More information

Subject Index. chromatography step, 125-

Subject Index. chromatography step, 125- A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade

More information

Evolution of Quality Assessments Recent Trends in FDA Queries. Mike Saleh, Pfizer Inc.

Evolution of Quality Assessments Recent Trends in FDA Queries. Mike Saleh, Pfizer Inc. Evolution of Quality Assessments Recent Trends in FDA Queries Mike Saleh, Pfizer Inc. Outline 1. Background 2. Assessment of Information Requests from Recent NDAs 3. Distribution of queries (by focus area)

More information

I. DEFINITION This training under Kilimanjaro School of Pharmacy Industrial Pharmacy Teaching Unit (IPTU) is an Advanced Training Program in Drug Development, Drug Manufacturing, Regulatory & Quality Compliance.

More information

18,000+ members/ subscribers. 34,000+ total readership with pass-along and show distributions

18,000+ members/ subscribers. 34,000+ total readership with pass-along and show distributions PRINT Pharmaceutical Engineering magazine R e a d e r s b y Wo r l d R e g i o n AUDIENCE Since 1980, Pharmaceutical Engineering magazine s mission has been to share with readers scientific and technical

More information

Development of paediatric formulations - points to consider

Development of paediatric formulations - points to consider Development of paediatric formulations - points to consider Workshop on Paediatric Formulations II London, 8 November 2011 Presented by: Ann Marie Kaukonen Scientific Administrator, Paediatric Medicines,

More information

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology

More information

Comparison of Guidelines of Indian GMP with WHO GMP

Comparison of Guidelines of Indian GMP with WHO GMP Comparison of Guidelines of Indian GMP with WHO GMP By Dr. Uma Vasireddy, M.Pharm,Ph.D.., Professor and Principal, KIPS,Wgl, INDIA 1 Outline of Presentation Introductory Elements Section wise Comparison

More information

Practical Considerations in Developing High Concentration Antibody Formulations

Practical Considerations in Developing High Concentration Antibody Formulations Practical Considerations in Developing High Concentration Antibody Formulations Qingyan Hu Formulation Development Group Regeneron Pharmaceuticals DDF Summit, 28 29 Aug 2017 Outline High concentration

More information

PRAXIS. A publication by Bioengineering AG

PRAXIS. A publication by Bioengineering AG PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.

More information

Derivation and Justification of Safety Thresholds

Derivation and Justification of Safety Thresholds Derivation and Justification of Safety Thresholds Douglas J. Ball, MS, DABT Chair, PQRI L&E Toxicology Subgroup Research Fellow, Safety Sciences - Pfizer, Inc. Agenda Basic Definitions Current Regulatory

More information

Stability of Biological Products

Stability of Biological Products Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth

More information

Paradigm Change in Manufacturing Operations SM

Paradigm Change in Manufacturing Operations SM Technical Report No. 54-3 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products

More information

CDER /OPQ Office of Surveillance Quality Metrics in Surveillance

CDER /OPQ Office of Surveillance Quality Metrics in Surveillance CDER /OPQ Office of Surveillance Quality Metrics in Surveillance Russell Wesdyk Acting Director Office of Surveillance Office of Surveillance Goals Builds from the shared vision A maximally efficient,

More information

Experience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014

Experience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014 Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A

More information

Roller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma

Roller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma Roller compactors for the pharmaceutical industry BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma Roller compactors for the pharmaceutical industry Compaction and granulation in the pharmaceutical

More information

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles

More information